Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm
Authors
Andrea M. Gross (ORCID: https://orcid.org/0000-0003-1646-4531)
Eva Dombi (ORCID: https://orcid.org/0000-0002-5323-6995)
Kyaw Sint
Brigitte C. Widemann (ORCID: https://orcid.org/0000-0002-9198-7175)
Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm
Andrea M. Gross, Eva Dombi, Kyaw Sint, Brigitte C. Widemann et al.
Citations
2 citations
Journal
Neuro-Oncology Advances
Topics
Neurofibromatosis and Schwannoma Cases
Field-Weighted Citation Impact (FWCI)
2.78
article
Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm
Andrea M. Gross, Eva Dombi, Kyaw Sint, Brigitte C. Widemann, Ayoade Adeyemi, Andrea Baldwin
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
Neuro-Oncology AdvancesVol. 7(1)
Institutions
AstraZeneca (Brazil) (BR), Frederick National Laboratory for Cancer Research (US), National Cancer Institute (US)